Atea Pharmaceuticals, Inc.
AVIR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593899
No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Atea Pharmaceuticals, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 115
- +8 vs. Q2 2025
- Shares held
- 53.2M
- +478.9K (+0.9%) vs. Q2 2025
- Total value
- $154.2M
- −$35.5M (−18.7%) vs. Q2 2025
- New holders
- 14
- 34 more added
- Sold out
- 6
- 39 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AVIR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 124 | $276.4M |
| Q1 2026 | 127 | $322.8M |
| Q4 2025 | 111 | $203.5M |
| Q3 2025 | 115 | $154.2M |
| Q2 2025 | 107 | $189.7M |
| Q1 2025 | 104 | $158.3M |
| Q4 2024 | 107 | $188.7M |
| Q3 2024 | 108 | $194.0M |
| Q2 2024 | 105 | $187.7M |
| Q1 2024 | 113 | $219.6M |
| Q4 2023 | 108 | $168.3M |
| Q3 2023 | 119 | $170.6M |
| Q2 2023 | 133 | $213.3M |
| Q1 2023 | 131 | $190.2M |
| Q4 2022 | 131 | $278.1M |
| Q3 2022 | 126 | $326.8M |
| Q2 2022 | 128 | $408.7M |
| Q1 2022 | 127 | $396.6M |
| Q4 2021 | 143 | $479.2M |
| Q3 2021 | 142 | $1.99B |
| Q2 2021 | 104 | $1.27B |
| Q1 2021 | 82 | $3.20B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Atea Pharmaceuticals, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 616,851 | $1.79M | 0.00% | −35,810−5.5% | Reduced |
| Charles Schwab Investment Management Inc | 624,984 | $1.81M | 0.00% | −10,298−1.6% | Reduced |
| Northern Trust Corp | 638,388 | $1.85M | 0.00% | −37,071−5.5% | Reduced |
| Two Sigma Advisers, LP | 796,200 | $2.31M | 0.00% | +95,300+13.6% | Added |
| Acadian Asset Management LLC | 969,773 | $2.81M | 0.00% | +51,927+5.7% | Added |
| Renaissance Technologies LLC | 1,227,900 | $3.56M | 0.00% | −6,200−0.5% | Reduced |
| Dimensional Fund Advisors LP | 1,540,716 | $4.47M | 0.00% | +129,453+9.2% | Added |
| State Street Corp | 1,783,976 | $5.17M | 0.00% | +7,575+0.4% | Added |
| Geode Capital Management, LLC | 1,899,737 | $5.51M | 0.00% | −25,836−1.3% | Reduced |
| Bain Capital Life Sciences Investors, LLC | 2,485,638 | $7.21M | 0.48% | 00.0% | Unchanged |
| Vanguard Group Inc | 4,709,275 | $13.7M | 0.00% | −177,946−3.6% | Reduced |
| Tang Capital Management LLC | 4,826,200 | $14.0M | 0.54% | −63,000−1.3% | Reduced |
| FMR LLC | 5,822,773 | $16.9M | 0.00% | +103,015+1.8% | Added |
| BML Capital Management, LLC | 7,473,963 | $21.7M | 19.94% | −135,849−1.8% | Reduced |
| BlackRock, Inc. | 8,459,220 | $24.5M | 0.00% | −209,307−2.4% | Reduced |
| Almitas Capital LLC | 0 | $0 | 0.00% | −445,386−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −57,759−100.0% | Sold out |
| Deutsche Bank AG | 0 | $0 | 0.00% | −42,967−100.0% | Sold out |
| Oxford Asset Management LLP | 0 | $0 | 0.00% | −40,787−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −5,470−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −400−100.0% | Sold out |